Kidney Cancer

>

Latest News

Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.
Belzutifan/Cabozantinib Elicits Promising Activity in Clear Cell RCC

January 10th 2025

Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.

Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC
Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC

January 3rd 2025

Discussing Immunotherapy Options in Advanced Non–Clear Cell RCC
Discussing Immunotherapy Options in Advanced Non–Clear Cell RCC

December 26th 2024

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.
FDA Approves New Formulation of Pazopanib Tablets in RCC, Sarcoma

December 5th 2024

Addressing Gaps in Education for Non–Clear Cell RCC
Addressing Gaps in Education for Non–Clear Cell RCC

November 19th 2024

Latest CME Events & Activities

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
2728293031